Skip to main content
. 2022 Nov 21;19(2):177–183. doi: 10.1038/s41567-022-01822-6

Extended Data Fig. 6. Lysophosphatidic acid pathway and pharmacological control of topological morphogenesis.

Extended Data Fig. 6

a, Workflow of experiment to test the role of lysophosphatidic acid (LPA) synthesis in organoid morphogenesis. Organoids were treated with varying concentrations of HA130, a small molecular inhibitor for ENPP2, with or without 250 nM retinoic acid (RA) during Day 2 to Day 4. Organoid morphologies were scored at Day 4. b, Representative examples of Day 4 organoids treated with varying concentrations of HA130 in the absence of RA. c, Representative examples of Day 4 organoids treated with varying concentrations of HA130 in the presence of RA. Images show maximum intensity projections of PODXL immunofluorescence signal. Organoid outer boundary (magenta) and apical surfaces (green) are shown for the corresponding sample. d, The temporal change in the number of lobules N normalized to the beginning of the movie for each organoid under the combination of RA and HA130 treatments. e, The temporal change in the total genus g of organoids under the combination of RA and HA130 treatments. The conditions +HA130 (n=3 organoids treated with 2000 nM HA130) and +RA, +HA130 (n=2 organoids treated with 250 nM RA and 2000 nM HA130) are presented together with the data for untreated and +RA conditions from Fig. 2. Scale bar, 100 μm.